Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: Relevance to neuroprotection in Parkinson's disease

Brain Research

Volumn 854, Issue 1-2, 2000, Pages 257-262

  Offen, Daniel ^a   Sherki, Yossi ^a   Melamed, Eldad ^a   Fridkin, Mati ^b   Brenneman, Douglas E ^c   Gozes, Illana ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c Lab Devmtl Neurbio   (United States)

Author keywords

Activity dependent neuroprotective protein; Activity dependent neurotrophic factor (ADNF); Buthionine sulfoximine (BSO); Dopamine (DA); Parkinson's disease (PD); Vasoactive intestinal peptide (VIP)

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AMYLOID BETA PROTEIN; BUTHIONINE SULFOXIMINE; DOPAMINE; GLUTATHIONE; NEUROTROPHIC FACTOR; OXIDOPAMINE; PEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CELL DEATH; CEREBELLUM; DOPAMINE; DOPAMINE ANTAGONISTS; GLUTATHIONE; HUMANS; MICE; NEUROBLASTOMA; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDOPAMINE; PARKINSON DISEASE; PC12 CELLS; RATS; TUMOR CELLS, CULTURED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0033964778     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02375-6     Document Type: Article

References (38)

1. Ashur-Fabian O., Perl O., Lilling G., Fridkin M., Gozes I. SNV, a lipophylic superactive VIP analog, acts through cGMP to promote neuronal survival. Peptides. 20:1999;629-633.
2. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., Bassan H., Blat C., Gibney G., Glazner G., Brenneman D.E., Gozes I. Complete sequence of a novel protein containing femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72:1999;1283-1293.
3. Bassan M., Zamostiano R., Giladi E., Davidson A., Wollman Y., Pitman J., Hauser J. The identification of secreted heat shock 60-like proteins from rat glial cell and a human neuroblastoma cell line. Neurosci. Lett. 250:1998;37-40.
4. Bornfreund E., Purner J.A. A simple quantitative procedure using monolayer cultures for cytotoxicity assay. J. Tiss. Cult. Methods. 9:1984;7-9.
5. Brenneman D.E., Eiden L.E. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc. Natl. Acad. Sci. USA. 83:1986;1159-1162.
6. Brenneman D.E., Gozes I. A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97:1996;2299-2307.
7. Brenneman D.E., Hauser J., Neale E., Rubinraut S., Fridkin M., Davidson A., Gozes I. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J. Pharmacol. Exp. Therap. 285:1998;619-627.
8. Brenneman D.E., Schultzberg M., Bartfai T., Gozes I. Cytokine regulation of neuronal survival. J. Neurochem. 58:1992;454-460.
9. Brenneman D.E., Westbrook G.L., Fitzgerald S.P., Ennist D.L., Elkins K.L., Ruff M.R., Pert C.B. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature. 131:1988;639-642.
10. +-induced dopaminergic neuronal cell death: role of caspases ROS, and JNK. J. Neurosci. Res. 57:1999;86-94.
11. D'Mello S.R., Gallili C., Ciotti T., Calisano P. Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin like growth factor 1 and cAMP. Proc. Natl. Acad. Sci. USA. 90:1993;10989-10993.
12. Everall I.P., Hudson L., Kerwin R.W. Decreased absolute levels of ascorbic acid and unaltered vasoactive intestinal polypeptide receptor binding in the frontal cortex in Acquired Immunodeficiency Syndrome. Neurosci. Lett. 224:1997;119-122.
13. Festoff B.W., Nelson J.B., Brenneman D.E. Prevention of activity-dependent neuronal death: vasoactive intestinal polypeptide stimulates astrocytes to secrete the thrombin-inhibiting neurotrophic serpin, protease nexin-1. J. Neurobiol. 30:1996;255-266.
14. Gozes I., Brenneman D.E. VIP molecular biology and neurobiological function. Mol. Neurobiol. 3:1989;201-236.
15. Gozes I., Brenneman D.E. Activity-dependent neurotrophic factor (ADNF): An extracellular neuroprotective chaperonin? J. Mol. Neurosci. 7:1996;235-244.
16. Gozes I., Bachar M., Bardea A., Davidson A., Rubinraut S., Fridkin M., Giladi E. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implication for early treatment of Alzheimer's disease. J. Neurobiol. 33:1997;329-342.
17. Gozes I., Bardea A., Reshef A., Zamostiano R., Zhukovsky S., Rubinraut S., Fridkin M., Brenneman D.E. Novel Neuroprotective strategy for Alzheimer's disease: inhalation of a fatty neuropeptide. Proc. Natl. Acad. Sci. USA. 93:1996;427-432.
18. Gozes I., Davidson A., Gozes Y., Mascolo R., Barth R., Warren D., Hauser J., Brenneman D.E. Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Dev. Brain Res. 99:1997;167-175.
19. Gozes I., Lilling G., Glazer R., Ticher A., Ashkenazi I.E., Davidson A., Rubinraut S., Fridkin M., Brenneman D.E. Superactive lipophilic peptides discriminate multiple VIP receptors. J. Pharmacol. Exper. Therap. 273:1995;161-167.
20. Gozes I., Perl O., Giladi E., Davidson A., Ashur-Fabian O., Rubinraut S., Fridkin M. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc. Natl. Acad. Sci. USA. 96:1999;4143-4148.
21. Gozes I., Shachter P., Shani Y., Giladi E. Vasoactive intestinal peptide gene expression from embryos to aging rats. Neuroendocrinology. 47:1988;27-31.
22. Gozes I., Shani Y., Rostene W.H. Developmental expression of the VIP-gene in brain and intestine. Mol. Brain Res. 2:1987;137-148.
23. Gressens P., Besse L., Robberecht P., Gozes I., Fridkin M., Evrard P. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives. J. Pharmacol. Exp. Ther. 288:1999;1207-1213.
24. Gressens P., Marret S., Hill J.M., Brenneman D.E., Gozes I., Fridkin M., Evrard P. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J. Clin. Invest. 100:1997;390-397.
25. Guo Q., Sebastian L., Sopher B.L., Miller M.W., Glazner G.W., Ware C.B., Martin G.M., Mattson M.P. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc. Natl. Acad. Sci. USA. 96:1999;4125-4130.
26. Jegou S., Javoy-Agid F., Delbende C., Tranchand-Bunel D., Coy D.H., Agid Y., Vaudry H. Regional distribution of vasoactive intestinal peptide in brains from normal and parkinsonian subjects. Peptides. 9:1988;787-793.
27. Lasher R.S., Zagon I.S. The effect of potassium on neuronal differentiation in cultures of dissociated newborn rat cerebellum. Brain Res. 41:1972;482-488.
28. Misra B.R., Misra H.P. Vasoactive intestinal peptide, a singlet oxygen Quencher. J. Biol. Chem. 265:1990;15371-15374.
29. Offen D., Ziv I., Sternin H., Melamed E., Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp. Neurol. 141:1996;32-39.
30. Parkinson's study group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:1993;176-183.
31. Paspalas C.D., Papadopoulos G.C. Ultrastructural evidence for combined action of noradrenaline and vasoactive intestinal polypeptide upon neurons, astrocytes, and blood vessels of the rat cerebral cortex. Brain Res. Bull. 45:1998;247-259.
32. Pellegri G., Magistretti P.J., Martin J. L VIP and PACAP potentiate the action of glutamate on BDNF expression in mouse cortical neurones. Eur. J. Neurosci. 10:1998;272-280.
33. d-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly (ADP-ribose) polymerase. Proc. Natl. Acad. Sci. USA. 93:1996;4688-4692.
34. Said S.I., Mutt V. Isolation from porcine intestinal wall of a vasoactive octacoaspeptide related to secretin and to glucagon. Eur. J. Biochem. 28:1972;199-204.
35. C.Y. Spong, D.T. Abebe, I. Gozes, D.E. Brenneman, J.M. Hill, Prevention of fetal alcohol syndrome with novel peptides, submitted for publication.
36. Stoddard S.L., Tyce G.M., Ahlskog J.E., Zinsmeister A.R., Nelson D.K., Carmichael S.W. Decreased levels of [met] enkephalin, neuropeptide y, substance p and vasoactive intestinal peptide in parkinsonian adrenal medula. Exp. Neurol. 114:1991;23-27.
37. Zamostiano R., Pinhasov A., Bassan M., Perl O., Steingart R.A., Atlas R., Brenneman D.E., Gozes I. A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism. Neurosci. Lett. 264:1999;9-12.
38. Ziv I., Melamed E., Nardi N., Luria D., Achiron A., Offen D., Barzilai A. Dopamine induces apoptosis like cell death in cultured sympathetic neurons: a possible novel pathogenic mechanism in Parkinson's disease. Neurosci. Lett. 170:1994;136-140.